Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CTHR Huge news after hours $3 tomorrow
http://finance.yahoo.com/news/Charles-Colvard-Signs-New-bw-781867952.html?x=0
This was a $20 stock a few years ago. Artifical diamonds a huge market.
IMOS $1.40 + $.167 $250 MM annual EBITDA
IMOS is next RAS and KFN. $150 MM annual free cash flow $250 MM EBITDA, 77 MM shares OS.
Huge depreciation charges skewing GAAP numbers but stocks valiued on cash flow.
$15 target.
IMOS $1.44 + $.21 $250 MM annual EBITDA
IMOS is next RAS and KFN. $150 MM annual free cash flow $250 MM EBITDA, 77 MM shares OS.
$15 target.
CYCC mentioned with Merck and Pfizer: will be MONSTER Monday:
http://seekingalpha.com/instablog/353981-michael-becker/63734-cyclin-dependent-cancer-confab-preview
At AACR, Cyclacel is introducing a second-generation CDK product candidate, which is currently in investigational new drug [IND]-directed development. The undisclosed molecule is a second generation oral CDK inhibitor with increased potency. Three abstracts related to both seliciclib and the second-generation compound are scheduled for presentation at AACR.
CYCC mentioned with Merck and Pfizer: will be monster Monday:
http://seekingalpha.com/instablog/353981-michael-becker/63734-cyclin-dependent-cancer-confab-preview
At AACR, Cyclacel is introducing a second-generation CDK product candidate, which is currently in investigational new drug [IND]-directed development. The undisclosed molecule is a second generation oral CDK inhibitor with increased potency. Three abstracts related to both seliciclib and the second-generation compound are scheduled for presentation at AACR.
CYCC mentioned with Merck and Pfizer: will be MONSTER Monday:
http://seekingalpha.com/instablog/353981-michael-becker/63734-cyclin-dependent-cancer-confab-preview
At AACR, Cyclacel is introducing a second-generation CDK product candidate, which is currently in investigational new drug [IND]-directed development. The undisclosed molecule is a second generation oral CDK inhibitor with increased potency. Three abstracts related to both seliciclib and the second-generation compound are scheduled for presentation at AACR.
CYCC going to go Bezerk off RNN momo
RNN and CYCC both are focusing on breakthrough CDK inhibitor drugs.
RNN is in pre clinical phase now has $240 MM market cap.
CYCC is about to file Phase 3 and has $70 MM market cap.
I think we'll see 1.50.
$1.20 after 16 stage frac results next week.
CHCI $2 target
Based on the Company's success in realigning its debt and operating expenses with current market realities, the Company anticipates that the combination of enhanced cash flow from improved unit settlements, the cash generated by rental operations, the cash generated by land sales and the cash received from the tax refund will be sufficient to sustain operations through 2010. Further, the Company believes that it will generate a significant recovery of invested capital as a result of the completion of unit sales at the Eclipse and Penderbrook projects and as a result of the judgment award, if upheld on appeal, and that these sources of capital will position the Company to capitalize on emerging opportunities in the Company's core market.
"We believe the success of our Strategic Realignment Plan has stabilized our company and will lead to Comstock being a stronger company that is well positioned to capitalize on new opportunities," said Christopher Clemente, Comstock's Chairman and Chief Executive Officer. "Overall, we have reduced total debt from approximately $340.0 million at September 30, 2006 to $68.0 million at December 31, 2009. Additional benefits of our Strategic Realignment Plan include: enhanced operating cashflow, reduced operating costs and the potential to operate profitably in the near term. We are confident that we are poised to continue the trend of profitable results which began in Q3 2009 as the benefits of our Strategic Realignment Plan impact results, and we continue working diligently toward our goal of rebuilding shareholder value through near and long term positive operating results."
1) ANALYST COMMENTS:
Hedge Fund $3 - $5 Target (March 26 2010)
http://www.themarketguardian.com/2010/03/radar-play-snss/
Jefferies $2 Target (Feb 12 2010)
Jefferies & Co raises their SNSS tgt to $2 from $1.50 saying they believe SNSS may have made progress in FDA negotiations over its Voreloxin registration strategy and design of pivotal AML trial. Firm says this should incrementally decrease regulatory risk and bring SNSS closer to a potential Voreloxin partnership or becoming an acquisition candidate.
2) MAJOR DRUG COMPANY INVESTMENT:
Bristol-Myers Squibb Company bought 3.7% in SNSS (February 2010)
http://ir.sunesis.com/sec.cfm
3) BUYOUT / PARTNERSHIPS
Sunesis Pharmaceuticals' Chief Financial Officer Eric Bjerkholt told Reuters that the company was already in talks for a partnership on Dec. 11, 2009. Now, 3 months passed and it's about time for the deal to close.
4) DRUG RESULTS. The following results are SPECTACULAR. Median survival INCREASED 7.8 months (DNDN's drug increases survival by 2 months)
a) Voreloxin demonstrated strong dose-dependent tumor growth inhibition (63-88%) in 10 of 11 solid tumor (breast, ovarian, colon, lung, gastric, and melanoma) xenograft models, 2 hematologic tumor xenograft models, 3 multidrug resistant tumor models and 3 murine syngeneic tumor models (Colon 26, Lewis Lung carcinoma, M5076 Ovarian Sarcoma). CONCLUSIONS: These data demonstrate that voreloxin is a broadly active anti-tumor agent in vitro and in vivo, with potent activity in aggressive and drug-resistant tumor models. Tens of billions of market opportunity!
b) Voreloxin works on patients that failed on Avastin in ovarian cancer.
c) 31% REMISSION RATE and Phase 3 Trial of Voreloxin in Acute Myeloid Leukemia (Voreloxin, unique anti-leukemic activity and tolerability).
d) The phase 1b/2 is even better; in which, the median survival rate is 7.8 months, and the 30 day and 60 day mortality rates are merely 1% and 8%. Yet no drug in the world has acheived such great results for this disease. The FDA will likely fast-track it.
DD Summary SNSS $.88 + $.11 32 Million volume
1) ANALYST COMMENTS:
Hedge Fund $3 - $5 Target (March 26 2010)
http://www.themarketguardian.com/2010/03/radar-play-snss/
Jefferies $2 Target (Feb 12 2010)
Jefferies & Co raises their SNSS tgt to $2 from $1.50 saying they believe SNSS may have made progress in FDA negotiations over its Voreloxin registration strategy and design of pivotal AML trial. Firm says this should incrementally decrease regulatory risk and bring SNSS closer to a potential Voreloxin partnership or becoming an acquisition candidate.
2) MAJOR DRUG COMPANY INVESTMENT:
Bristol-Myers Squibb Company bought 3.7% in SNSS (February 2010)
http://ir.sunesis.com/sec.cfm
3) BUYOUT / PARTNERSHIPS
Sunesis Pharmaceuticals' Chief Financial Officer Eric Bjerkholt told Reuters that the company was already in talks for a partnership on Dec. 11, 2009. Now, 3 months passed and it's about time for the deal to close.
4) DRUG RESULTS. The following results are SPECTACULAR. Median survival INCREASED 7.8 months (DNDN's drug increases survival by 2 months)
a) Voreloxin demonstrated strong dose-dependent tumor growth inhibition (63-88%) in 10 of 11 solid tumor (breast, ovarian, colon, lung, gastric, and melanoma) xenograft models, 2 hematologic tumor xenograft models, 3 multidrug resistant tumor models and 3 murine syngeneic tumor models (Colon 26, Lewis Lung carcinoma, M5076 Ovarian Sarcoma). CONCLUSIONS: These data demonstrate that voreloxin is a broadly active anti-tumor agent in vitro and in vivo, with potent activity in aggressive and drug-resistant tumor models. Tens of billions of market opportunity!
b) Voreloxin works on patients that failed on Avastin in ovarian cancer.
c) 31% REMISSION RATE and Phase 3 Trial of Voreloxin in Acute Myeloid Leukemia (Voreloxin, unique anti-leukemic activity and tolerability).
d) The phase 1b/2 is even better; in which, the median survival rate is 7.8 months, and the 30 day and 60 day mortality rates are merely 1% and 8%. Yet no drug in the world has acheived such great results for this disease. The FDA will likely fast-track it.
SNSS $.97 + $.21 $3 Hedge Fund target
http://www.themarketguardian.com/2010/03/radar-play-snss/
CPWM $2.2 will report $.60 - $.70 EPS for Q4
Fourth Quarter Outlook — Continuing Operations
For the fourth quarter of fiscal 2009, the Company expects net sales in the range of $314 million to $330 million, based on same store sales in the range of a 4% decrease to a 1% increase. The Company is expecting a year-over-year decrease in January sales since it will not repeat the inventory clearance event that occurred in January last year that generated strong temporary traffic increases. Gross profit margin for the fourth quarter is expected to be 330 to 380 basis points higher than last year. On a normalized basis, gross profit margin is expected to increase 70 to 120 basis points over last year when the impact of the $9 million charge related to the inventory clearance event is excluded.
For the fourth quarter of fiscal 2009, the Company is projecting income from continuing operations before interest and taxes in the range of $8 million to $14 million versus a loss of $10.9 million last year. Depreciation and net interest expense are projected to be $6 million and $3 million respectively, resulting in EBITDA in the range of $14 million to $20 million versus a negative $3 million EBITDA in the fourth quarter of last year.
Additionally, the Company will record a tax receivable on the balance sheet in the fourth quarter for the estimated $12 million tax refund. Due to the full valuation allowance, the benefit of the income tax refund will have a positive impact on net income in the fourth quarter which is not included in the estimated guidance range of $8 million to $14 million referred to above.
CPWM $2.2 will report $.60 - $.70 EPS for Q4
Fourth Quarter Outlook — Continuing Operations
For the fourth quarter of fiscal 2009, the Company expects net sales in the range of $314 million to $330 million, based on same store sales in the range of a 4% decrease to a 1% increase. The Company is expecting a year-over-year decrease in January sales since it will not repeat the inventory clearance event that occurred in January last year that generated strong temporary traffic increases. Gross profit margin for the fourth quarter is expected to be 330 to 380 basis points higher than last year. On a normalized basis, gross profit margin is expected to increase 70 to 120 basis points over last year when the impact of the $9 million charge related to the inventory clearance event is excluded.
For the fourth quarter of fiscal 2009, the Company is projecting income from continuing operations before interest and taxes in the range of $8 million to $14 million versus a loss of $10.9 million last year. Depreciation and net interest expense are projected to be $6 million and $3 million respectively, resulting in EBITDA in the range of $14 million to $20 million versus a negative $3 million EBITDA in the fourth quarter of last year.
Additionally, the Company will record a tax receivable on the balance sheet in the fourth quarter for the estimated $12 million tax refund. Due to the full valuation allowance, the benefit of the income tax refund will have a positive impact on net income in the fourth quarter which is not included in the estimated guidance range of $8 million to $14 million referred to above.
Cost Plus, Inc. is a leading specialty retailer of casual home living and entertaining products. As of December 3, 2009, the Company operated 269 stores in 30 states versus 278 stores (after adjusting for the 18 stores now classified as discontinued operations) in 30 states at the end of third quarter of fiscal 2008.
IGOI:NASDAQ $1.56, WalMart Deal, 400% sales increase forecast
http://www.valueplays.net/2010/03/17/valueplays-tv-316/
IGOI has $1.25 / share cash and no debt with a patenyted suite of "green" electronic products. Was $10 a fgew years ago. Established distribution network of 5800 Radio Shacks and now the addition of 3550 Walmart stores is huge. I can see a strong push to get into Best Buy this year as well.
As the unwinding of the Targus contract took place the margins increased at the expense of revenue growth. As the shift to direct sales is made and new distribution lines are created revenues will increase and margins will be higher than the previous sales model.
This is a screaming buy at these levels. Could see $6 by years end.
IGOI:NASDAQ $1.56, WalMart Deal, 400% sales increase forecast
http://www.valueplays.net/2010/03/17/valueplays-tv-316/
IGOI has $1.25 / share cash and no debt with a patenyted suite of "green" electronic products. Was $10 a fgew years ago. Established distribution network of 5800 Radio Shacks and now the addition of 3550 Walmart stores is huge. I can see a strong push to get into Best Buy this year as well.
As the unwinding of the Targus contract took place the margins increased at the expense of revenue growth. As the shift to direct sales is made and new distribution lines are created revenues will increase and margins will be higher than the previous sales model.
This is a screaming buy at these levels. Could see $6 by years end.
IGOI:NASDAQ $1.56, WalMart Deal, 400% sales increase forecast
http://www.valueplays.net/2010/03/17/valueplays-tv-316/
IGOI has $1.25 / share cash and no debt with a patenyted suite of "green" electronic products. Was $10 a fgew years ago. Established distribution network of 5800 Radio Shacks and now the addition of 3550 Walmart stores is huge. I can see a strong push to get into Best Buy this year as well.
As the unwinding of the Targus contract took place the margins increased at the expense of revenue growth. As the shift to direct sales is made and new distribution lines are created revenues will increase and margins will be higher than the previous sales model.
This is a screaming buy at these levels. Could see $6 by years end.
SNSS $.83 + $.10 Yahoo post: Just starting
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_S/threadview?m=tm&bn=26982&tid=27113&mid=27113&tof=28&frt=1
SMTX $2.48 + $.28 will report $.25 EPS next Quarter: $6 in no time
SMTX announced $.14 EPS in Q4 2009. The CEO said sales will ramp up further in the next few quarters.
SMTX has slashed costs to the bone by closing its Boston plant. They will now grow revenues and MARGINS, with the cheap labor pool in the China and Mexico. I expect SMTX will approach $60 MM sales in Q1 2010 with higher margins and will earn $.25 - $.30 per share.
SMTX $2.48 + $.28 wiill report $.25 EPS next Quarter: $6 in no time
SMTX announced $.14 EPS in Q4 2009. The CEO said sales will ramp up further in the next few quarters.
SMTX has slashed costs to the bone by closing its Boston plant. They will now grow revenues and MARGINS, with the cheap labor pool in the China and Mexico. I expect SMTX will approach $60 MM sales in Q1 2010 with higher margins and will earn $.25 - $.30 per share.
SMTX $2.48 + $.28 wiill report $.25 EPS next Quarter: $6 in no time
SMTX announced $.14 EPS in Q4 2009. The CEO said sales will ramp up further in the next few quarters.
SMTX has slashed costs to the bone by closing its Boston plant. They will now grow revenues and MARGINS, with the cheap labor pool in the China and Mexico. I expect SMTX will approach $60 MM sales in Q1 2010 with higher margins and will earn $.25 - $.30 per share.
SMTX $2.4 + $.75 $8 Target
SMTX is up 50% today, but is still trading at a huge discount.
SMTX announced $.14 EPS in Q4 2009. The CEO said 2010 sales will ramp up further.
SMTX HAS THE POTENTIAL TO EARN $.80 - $1.00 IN 2010.
SMTX trades at a P/S ratio of 0.15 compared to the Industry average of 0.63. If SMTX traded at even HALF the sector average it would be $5.
The EMS sector is BOOMING driven by computer upgrades induced by Windows 7. IEC, CLS, SANM have posted best results in years, and ahve risen 500%.
The SMTX CEO, John Caldwell, is a corporate turnaround legend. He turned computer company GEAC computer around, it rose from $1 to $11 and was bought out.
The 2 most successful U.S. hedge funds- Bain Capital and Renaissance Capital, own SMTX. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
SMTX has slashed costs to the bone by closing its Boston plant. They will now be able to grow revenues and more importantly, MARGINS, with the cheap labor pool in the China and Mexico. I expect when SMTX hits $60 MM sales again it will have MUCH higher margins and could earn $.30 per share.
SMTX has a tightly held 12 Million float. It can move very fast, in 2005 went from $1 to over $3.50 in a few weeks. It was $8 in 2006.
In short, SMTX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 12 MM share float
- $35 MM market cap
- $200 MM + revenues
- Last CC: Healthy increase in backlog
- Last CC: Revenues and net income will be go up this quarter. Profitable again.
- Last CC: Customers, new and old, expected to ramp up production in 2010
- Traded at $8+ two years ago
- Major players in sector (FLEX, JBL, SANM) have gained up to 500% in 2009 while SMTX is still under the radar
- Frequently mentioned as acquisition candidate because of heavy industry consolidation
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
SMTX $2.4 + $.75 $8 Target
SMTX is up 50% today, but is still trading at a huge discount.
SMTX announced $.14 EPS in Q4 2009. The CEO said 2010 sales will ramp up further.
SMTX HAS THE POTENTIAL TO EARN $.80 - $1.00 IN 2010.
SMTX trades at a P/S ratio of 0.15 compared to the Industry average of 0.63. If SMTX traded at even HALF the sector average it would be $5.
The EMS sector is BOOMING driven by computer upgrades induced by Windows 7. IEC, CLS, SANM have posted best results in years, and ahve risen 500%.
The SMTX CEO, John Caldwell, is a corporate turnaround legend. He turned computer company GEAC computer around, it rose from $1 to $11 and was bought out.
The 2 most successful U.S. hedge funds- Bain Capital and Renaissance Capital, own SMTX. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
SMTX has slashed costs to the bone by closing its Boston plant. They will now be able to grow revenues and more importantly, MARGINS, with the cheap labor pool in the China and Mexico. I expect when SMTX hits $60 MM sales again it will have MUCH higher margins and could earn $.30 per share.
SMTX has a tightly held 12 Million float. It can move very fast, in 2005 went from $1 to over $3.50 in a few weeks. It was $8 in 2006.
In short, SMTX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 12 MM share float
- $35 MM market cap
- $200 MM + revenues
- Last CC: Healthy increase in backlog
- Last CC: Revenues and net income will be go up this quarter. Profitable again.
- Last CC: Customers, new and old, expected to ramp up production in 2010
- Traded at $8+ two years ago
- Major players in sector (FLEX, JBL, SANM) have gained up to 500% in 2009 while SMTX is still under the radar
- Frequently mentioned as acquisition candidate because of heavy industry consolidation
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
SMTX DD Info: $8 Target SMTX is up 50% today, but is still trading at a huge discount.
SMTX announced $.14 EPS in Q4 2009. The CEO said 2010 sales will ramp up further.
SMTX HAS THE POTENTIAL TO EARN $.80 - $1.00 IN 2010.
SMTX trades at a P/S ratio of 0.15 compared to the Industry average of 0.63. If SMTX traded at even HALF the sector average it would be $5.
The EMS sector is BOOMING driven by computer upgrades induced by Windows 7. IEC, CLS, SANM have posted best results in years, and ahve risen 500%.
The SMTX CEO, John Caldwell, is a corporate turnaround legend. He turned computer company GEAC computer around, it rose from $1 to $11 and was bought out.
The 2 most successful U.S. hedge funds- Bain Capital and Renaissance Capital, own SMTX. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
SMTX has slashed costs to the bone by closing its Boston plant. They will now be able to grow revenues and more importantly, MARGINS, with the cheap labor pool in the China and Mexico. I expect when SMTX hits $60 MM sales again it will have MUCH higher margins and could earn $.30 per share.
SMTX has a tightly held 12 Million float. It can move very fast, in 2005 went from $1 to over $3.50 in a few weeks. It was $8 in 2006.
In short, SMTX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 12 MM share float
- $35 MM market cap
- $200 MM + revenues
- Last CC: Healthy increase in backlog
- Last CC: Revenues and net income will be go up this quarter. Profitable again.
- Last CC: Customers, new and old, expected to ramp up production in 2010
- Traded at $8+ two years ago
- Major players in sector (FLEX, JBL, SANM) have gained up to 500% in 2009 while SMTX is still under the radar
- Frequently mentioned as acquisition candidate because of heavy industry consolidation
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
SMTX HUGE earnings $.14 $4 tomorrow
http://finance.yahoo.com/news/SMTC-Reports-Fourth-Quarter-prnews-90310782.html?x=0
SMTX $1.65 close HUGE earnings $.14 $4 tomorrow
http://finance.yahoo.com/news/SMTC-Reports-Fourth-Quarter-prnews-90310782.html?x=0
SMTX HUGE earnings $.14 $4 tomorrow
http://finance.yahoo.com/news/SMTC-Reports-Fourth-Quarter-prnews-90310782.html?x=0
YRCW $.47 + $.07 106 Million volume (S + P $1.50 target)
You will NEVER see a buying oppotunity again like YRCW in your lifetime.
1) YRCW has SLASHED costs to the bone. Further, through the debt EXCHANGE, $500 million in debt has been ELIMINATED. YRCW now has the best cost structure and balance sheet in YEARS.
2) YRCW CEO said YRCW will be cash flow positive by Q2 and PROFITABLE by Q3.
3) With 1.05 Billion shares OS, YRCW trades at a Price / Sales ratio of 0.1 compared to the Industry average of 0.49. IF YRCW TRADED AT INDUSTRY AVERAGE PRICE / SALES RATIO IT WOULD BE A $2.50 STOCK.
4) Standard + Poors, a conservative bond rating agency recently issued a $1.50 target on YRCW.
YRCW the last great bargain from the 2008 crisis
YRCW:NASDAQ 55 MM volume $.45 + $.05 S + P $1.50 tarhet
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_Y/threadview?m=tm&bn=27297&tid=89452&mid=89452&tof=104&frt=1
YRCW:NASDAQ $.41 50 MM volume S + P 41.50 target
See Research Report
https://research.ameritrade.com/wwws/com...
Due to restructuring efforts and declines in
shareholders' equity, we think price-to-sales is
a more appropriate valuation measure than
price-to-book value. Applying a ratio of 0.4X, a
discount to the historical peer average, to our
four-quarter forward sales per share estimate,
and using the 1.3 billion estimate for shares outstanding
yields a value near $1.50, which is our
12-month target price.
YTCW:NASDAQ $.41 50 MM volume S + P 41.50 target
See Research Report
https://research.ameritrade.com/wwws/com...
Due to restructuring efforts and declines in
shareholders' equity, we think price-to-sales is
a more appropriate valuation measure than
price-to-book value. Applying a ratio of 0.4X, a
discount to the historical peer average, to our
four-quarter forward sales per share estimate,
and using the 1.3 billion estimate for shares outstanding
yields a value near $1.50, which is our
12-month target price.
Authorized share increase has nothing to do woth issued shares.
Every NASDAQ company has way more authorized than issued.
YRCW $.40 S&P target $1.50 70 MM volume
See Research Report
https://research.ameritrade.com/wwws/com...
Due to restructuring efforts and declines in
shareholders' equity, we think price-to-sales is
a more appropriate valuation measure than
price-to-book value. Applying a ratio of 0.4X, a
discount to the historical peer average, to our
four-quarter forward sales per share estimate,
and using the 1.3 billion estimate for shares outstanding
yields a value near $1.50, which is our
12-month target price.
YRCW $.40 S&P target $1.50 70 MM volume
See Research Report
https://research.ameritrade.com/wwws/com...
Due to restructuring efforts and declines in
shareholders' equity, we think price-to-sales is
a more appropriate valuation measure than
price-to-book value. Applying a ratio of 0.4X, a
discount to the historical peer average, to our
four-quarter forward sales per share estimate,
and using the 1.3 billion estimate for shares outstanding
yields a value near $1.50, which is our
12-month target price.
YRCW $.40 S&P target $1.50 70 MM volume
See Research Report
https://research.ameritrade.com/wwws/com...
Due to restructuring efforts and declines in
shareholders' equity, we think price-to-sales is
a more appropriate valuation measure than
price-to-book value. Applying a ratio of 0.4X, a
discount to the historical peer average, to our
four-quarter forward sales per share estimate,
and using the 1.3 billion estimate for shares outstanding
yields a value near $1.50, which is our
12-month target price.
RNN $.83 +$.08 TWO bullish articles:
http://finance.yahoo.com/news/Rexahn-Pharmaceuticals-Amex-iw-3464506009.html?x=0&.v=1
http://finance.yahoo.com/news/Rexahn-Pharmaceuticals-Amex-iw-3464506009.html?x=0&.v=1
Most undervalued biotech firm! 9-Feb-10 10:40 pm I have been doing due diligence on this company since late last year. The company has three breakthrough products in phase 2. In fact two of them have successfully completed the phase 2a or proof of concept phase which makes those products very viable licensing targets for big pharma. These products, Serdaxin and Zoraxel, are the same active ingredient. Serdaxin is a novel and new method of treating depression without any major side effects. This is an $11 billion worldwide market yet it does not effectively treat two thirds of all depressed patients. Serdaxin since it works on both seratonin and dopamine is the only clinically evaluated drug that has successfully been able to increase both. This allows mild to moderate depression to be treated without any major relapses for the patients that are not just constantly negative but who have lost their positive state or have both attributes. In the next 4 years over $5 billion of that $11 billion will come off patent. This means that RNN is a prime candidate to replace those compounds and expand the market to solve patients needs who did not do well on prozac or zoloft. In addition it appears Serdaxin also is a neuroprotector. Thc company plans on starting phase 2 trials on parkinson within months. In animals it has shown the ability to keep neuronal cells from dying from Parkinsons or Alzheimers disease. This drug is safe and effective so it will be easy and fast to see if this is true. Depression is in 60% of all parkinson and alzheimer patients. More exciting is Zoraxel. It is a novel way to treat Erectile Dysfunction. It works on the Libido(desire) as well as erection and ejaculation. Viagra and its bretheren only work on blood flow not desire. This makes you want to have sex. About half the patients do not respond to Viagra. This drug works on all patient types. The phase 2a top line results were positive but in April you will see the real results and a new drug star will be born. This is the same active as serdaxin. This compound is a true wonder drug. It will capture the public's imagination when the final results will be reported. In addition this market is over $ 5 billion worldwide and Viagra is off patent in two years. Pfe and the others will need a new compound that works on many more patients in a more effective and pleasurable way. Zoraxel will be the subject of a bidding war among the big Pharma companies. These two drugs attack a combined $16 billion market that a large part is going generic and will need new more effective compounds. They have great phase 2a results and are very safe. Watch how the big pharma companies kill themselves to deal with RNN once they find out about them. This company has been below the radar screen. However they are opening up to the world and look out. Just to start this company should be a $300 million to $500 million market cap now. That implies a $4-$7/shr price right away.
RNN $.83 +$.08 TWO bullish articles:
http://finance.yahoo.com/news/Rexahn-Pharmaceuticals-Amex-iw-3464506009.html?x=0&.v=1
http://finance.yahoo.com/news/Rexahn-Pharmaceuticals-Amex-iw-3464506009.html?x=0&.v=1
Most undervalued biotech firm! 9-Feb-10 10:40 pm I have been doing due diligence on this company since late last year. The company has three breakthrough products in phase 2. In fact two of them have successfully completed the phase 2a or proof of concept phase which makes those products very viable licensing targets for big pharma. These products, Serdaxin and Zoraxel, are the same active ingredient. Serdaxin is a novel and new method of treating depression without any major side effects. This is an $11 billion worldwide market yet it does not effectively treat two thirds of all depressed patients. Serdaxin since it works on both seratonin and dopamine is the only clinically evaluated drug that has successfully been able to increase both. This allows mild to moderate depression to be treated without any major relapses for the patients that are not just constantly negative but who have lost their positive state or have both attributes. In the next 4 years over $5 billion of that $11 billion will come off patent. This means that RNN is a prime candidate to replace those compounds and expand the market to solve patients needs who did not do well on prozac or zoloft. In addition it appears Serdaxin also is a neuroprotector. Thc company plans on starting phase 2 trials on parkinson within months. In animals it has shown the ability to keep neuronal cells from dying from Parkinsons or Alzheimers disease. This drug is safe and effective so it will be easy and fast to see if this is true. Depression is in 60% of all parkinson and alzheimer patients. More exciting is Zoraxel. It is a novel way to treat Erectile Dysfunction. It works on the Libido(desire) as well as erection and ejaculation. Viagra and its bretheren only work on blood flow not desire. This makes you want to have sex. About half the patients do not respond to Viagra. This drug works on all patient types. The phase 2a top line results were positive but in April you will see the real results and a new drug star will be born. This is the same active as serdaxin. This compound is a true wonder drug. It will capture the public's imagination when the final results will be reported. In addition this market is over $ 5 billion worldwide and Viagra is off patent in two years. Pfe and the others will need a new compound that works on many more patients in a more effective and pleasurable way. Zoraxel will be the subject of a bidding war among the big Pharma companies. These two drugs attack a combined $16 billion market that a large part is going generic and will need new more effective compounds. They have great phase 2a results and are very safe. Watch how the big pharma companies kill themselves to deal with RNN once they find out about them. This company has been below the radar screen. However they are opening up to the world and look out. Just to start this company should be a $300 million to $500 million market cap now. That implies a $4-$7/shr price right away.
RNN $.83 +$.08 TWO bullish articles:
http://finance.yahoo.com/news/Rexahn-Pharmaceuticals-Amex-iw-3464506009.html?x=0&.v=1
http://finance.yahoo.com/news/Rexahn-Pharmaceuticals-Amex-iw-3464506009.html?x=0&.v=1
Most undervalued biotech firm! 9-Feb-10 10:40 pm I have been doing due diligence on this company since late last year. The company has three breakthrough products in phase 2. In fact two of them have successfully completed the phase 2a or proof of concept phase which makes those products very viable licensing targets for big pharma. These products, Serdaxin and Zoraxel, are the same active ingredient. Serdaxin is a novel and new method of treating depression without any major side effects. This is an $11 billion worldwide market yet it does not effectively treat two thirds of all depressed patients. Serdaxin since it works on both seratonin and dopamine is the only clinically evaluated drug that has successfully been able to increase both. This allows mild to moderate depression to be treated without any major relapses for the patients that are not just constantly negative but who have lost their positive state or have both attributes. In the next 4 years over $5 billion of that $11 billion will come off patent. This means that RNN is a prime candidate to replace those compounds and expand the market to solve patients needs who did not do well on prozac or zoloft. In addition it appears Serdaxin also is a neuroprotector. Thc company plans on starting phase 2 trials on parkinson within months. In animals it has shown the ability to keep neuronal cells from dying from Parkinsons or Alzheimers disease. This drug is safe and effective so it will be easy and fast to see if this is true. Depression is in 60% of all parkinson and alzheimer patients. More exciting is Zoraxel. It is a novel way to treat Erectile Dysfunction. It works on the Libido(desire) as well as erection and ejaculation. Viagra and its bretheren only work on blood flow not desire. This makes you want to have sex. About half the patients do not respond to Viagra. This drug works on all patient types. The phase 2a top line results were positive but in April you will see the real results and a new drug star will be born. This is the same active as serdaxin. This compound is a true wonder drug. It will capture the public's imagination when the final results will be reported. In addition this market is over $ 5 billion worldwide and Viagra is off patent in two years. Pfe and the others will need a new compound that works on many more patients in a more effective and pleasurable way. Zoraxel will be the subject of a bidding war among the big Pharma companies. These two drugs attack a combined $16 billion market that a large part is going generic and will need new more effective compounds. They have great phase 2a results and are very safe. Watch how the big pharma companies kill themselves to deal with RNN once they find out about them. This company has been below the radar screen. However they are opening up to the world and look out. Just to start this company should be a $300 million to $500 million market cap now. That implies a $4-$7/shr price right away.